STAT+：Kymera湿疹试验即将公布的结果，是挑战Dupixent的关键时刻
摘要
过去十年间，赛诺菲和再生元公司的Dupixent已成为免疫学领域最畅销的药物，带来了数百亿美元的收入，同时改变了目前140万接受该疗法治疗湿疹、哮喘和慢性阻塞性肺病等疾病的患者的治疗结局。但投资者和医生正密切关注一种有望与这款制药重磅药物抗衡的实验性疗法，一项关键研究的结果即将揭晓。马萨诸塞州生物技术公司Kymera Therapeutics计划在年底前公布其主打候选药物KT-621治疗湿疹的一项中期临床试验数据。投资银行Jefferies的市场分析师使用免疫学和炎症性疾病的常用简称，称即将公布的结果“是最……”
English
Over the past decade, Sanofi and Regeneron’s Dupixent has become the top-selling drug in immunology, bringing in tens of billions in revenue while transforming outcomes for the 1.4 million patients currently on the therapy for conditions including eczema, asthma, and chronic obstructive pulmonary disease. But investors and doctors are intensely following an experimental therapy positioned to rival the pharma blockbuster, with results from a key study fast approaching. Massachusetts biotech Kymera Therapeutics plans to announce data from a mid-stage clinical trial of its lead asset, KT-621, in eczema before the end of the year. Market analysts for the investment bank Jefferies, using common shorthand for immunology and inflammatory disorders, have called the upcoming results “one of the mos